There are 108 resources available
1019O - Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Nehal Lakhani
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1020O - A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours
Presenter: Manish Sharma
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1021O - Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies
Presenter: Michael Millward
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1156O - Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)
Presenter: Jianming Xu
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
Why do we need phase I clinical trials?
Presenter: Martijn Lolkema
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Slides
Webcast
From referral for to participation in phase I clinical trials: Patient journeys and preliminary results in the development of an online value clarification tool
Presenter: Liza Van Lent
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Slides
Webcast
Q&A live discussion
Presenter: Ruben Martin Payo
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Webcast
Invited Discussant 1257O and 1258O
Presenter: Colin Lindsay
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Lecia Sequist
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Webcast
Invited Discussant LBA50 and 1259O
Presenter: Lecia Sequist
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Webcast